TABLE 3.
Seroconversion for vibriocidal assay and CT ELISAa
| Group | n | No. (%) of subjects who seroconverted
|
|
|---|---|---|---|
| Vibriocidal assay | CT ELISA | ||
| All vaccinees | 40 | 39 (97) | 11 (28) |
| All placebo recipients | 19 | 0 (0) | 0 (0) |
| Subjects who participated in the challenge study | |||
| Vaccinees | 24 | 23 (96) | 7 (29) |
| Placebo recipients | 12 | 0 (0) | 0 (0) |
| Subjects who did not participate in the challenge study | |||
| Vaccinees | 16 | 16 (100) | 4 (25) |
| Placebo recipients | 7 | 0 (0) | 0 (0) |
a
Seroconversion defined as a fourfold increase in titer pre- versus postimmunization for the vibriocidal assay and as 0.2 OD unit increase for CT ELISA.